SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews

Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients

(2020) Shih-Chieh Shao et al.   Cardiovascular Diabetology

Effects of SGLT2 Inhibitors on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Meta‐Analysis of Randomized Controlled Trials

(2020) Baodi Xing et al.   Journal of Diabetes Investigation

Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review

(2020) Chelsea S. Pan et al.   Frontiers in Endocrinology

Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data

(2020) Rohit Loomba et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Non‐alcoholic fatty liver disease is associated with cardiovascular disease in subjects with different glucose tolerance

(2020) Teresa Vanessa Fiorentino et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications

(2020) Giovanni Targher et al.   GUT

Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis

(2020) Marco Castellana et al.   Cardiovascular Diabetology

Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications

(2019) A.J. Scheen   DIABETES & METABOLISM

The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis

(2019) Zobair M. Younossi et al.   JOURNAL OF HEPATOLOGY

Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?

(2019) Niki Katsiki et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Effects of Sodium Glucose Co‐transporter 2 Inhibitors on Serum Alanine Aminotransferase Values in Type 2 Diabetes Patients: A Multi‐Institutional Cohort Study

(2019) Shih‐Chieh Shao et al.   DIABETES OBESITY & METABOLISM

The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma

(2019) Teruo Jojima et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?

(2019) Shih-Chieh Shao et al.   BMJ Open Diabetes Research & Care

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

(2018) Mohammad Shafi Kuchay et al.   DIABETES CARE

Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study

(2018) Paul Chi Ho Lee et al.   Diabetes Therapy

Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study

(2018) Paul Chi Ho Lee et al.   Diabetes Therapy

Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease

(2018) Fabrice Bonnet et al.   DIABETES & METABOLISM

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial

(2018) Naveed Sattar et al.   DIABETOLOGIA

Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis

(2018) Simona Leoni et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies

(2018) Norbert Stefan et al.   Lancet Diabetes & Endocrinology

Impact of SGLT2 inhibitor to histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus

(2018) Norio Akuta et al.   HEPATOLOGY RESEARCH

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Treatment of NAFLD with diet, physical activity and exercise

(2017) Manuel Romero-Gómez et al.   JOURNAL OF HEPATOLOGY

AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both

(2017) Beverley J Shea et al.   BMJ-British Medical Journal

AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both

(2017) Beverley J Shea et al.   BMJ-British Medical Journal

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

(2016) Kenneth Cusi et al.   ANNALS OF INTERNAL MEDICINE

Effect of canagliflozin on liver function tests in patients with type 2 diabetes

(2016) L.A. Leiter et al.   DIABETES & METABOLISM

Non-alcoholic fatty liver disease and diabetes

(2016) Jonathan M. Hazlehurst et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport

(2015) Sunder Mudaliar et al.   DIABETES CARE

Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies

(2015) Wenjuan Tang et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels

(2015) Paola Portillo-Sanchez et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013

(2013) G. Schernthaner et al.   DIABETES CARE

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

(2012) Naga Chalasani et al.   HEPATOLOGY

Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: A systematic review and meta-analysis of cohort studies

(2011) Chenggang Wang et al.   INTERNATIONAL JOURNAL OF CANCER

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE